Channel-blocking mechanism ensures specific blockade of synaptic transmission.
V I
VI
Skok
D000818:Animals; D001030:Apamin / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects; D005728:Ganglia, Sympathetic / Q000187:drug effects; D005730:Ganglionic Blockers / Q000494:pharmacology*; D018738:Hexamethonium; D006584:Hexamethonium Compounds / Q000494:pharmacology; D007473:Ion Channels / Q000187:drug effects*; D009469:Neuromuscular Junction / Q000187:drug effects; D017459:Receptors, Amino Acid; D011956:Receptors, Cell Surface / Q000187:drug effects; D011978:Receptors, Nicotinic / Q000187:drug effects; D013569:Synapses / Q000187:drug effects*; D009435:Synaptic Transmission / Q000187:drug effects*; D014403:Tubocurarine / Q000494:pharmacology
D005730:Ganglionic Blockers; D006584:Hexamethonium Compounds; D007473:Ion Channels; D017459:Receptors, Amino Acid; D011956:Receptors, Cell Surface; D011978:Receptors, Nicotinic; D001030:Apamin; D018738:Hexamethonium; D014403:Tubocurarine